Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, because that all-too-familiar routine of meetings, deadlines and what-not has returned. To cope, we are relying, as always, on that mandatory cup of stimulation. Southern Pecan is our choice today and, of course, we invite you to join us. Meanwhile, here is the usual menu of tidbits. Have a good day and keep in touch…
Johnson & Johnson defeated a lawsuit claiming it had improperly designed its Tylenol pain reliever, in the first case to go to trial over the link between the widely used over-the-counter drug and liver damage; The FDA declined to approve a dry-eye drug being developed by Shire, dealing a blow to its most important pipeline medicine; and the FDA approved an antidote to Pradaxa, the Boehringer Ingelheim bloodthinner, to reverse the effects of the treatment during emergency situations.